ReviewNature protocols2026
Profiling active RNA polymerase II transcription start sites from total RNA by capped small RNA sequencing (csRNA-seq).
Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
High-resolution mapping of active RNA polymerase II transcription initiation provides a dynamic view of gene expression and reveals the entire spectrum of RNA transcripts-from stable mRNAs to transient enhancer RNAs-which is critical for understanding gene regulation, deciphering transcriptional programs and defining regulatory element function. Here we present a detailed protocol for capped small RNA sequencing (csRNA-seq). Starting with total RNA, which can be readily isolated from fresh, frozen or fixed cells, tissues or patient samples, csRNA-seq selectively enriches for actively initiating 5'-capped RNA polymerase II transcripts. This approach captures both initiating stable protein-coding RNAs and non-coding RNAs, as well as rapidly degraded, transient transcripts such as enhancer or promoter divergent RNAs, providing a comprehensive snapshot of active cis-regulatory elements and facilitating the study of underlying regulatory mechanisms with high sensitivity. The protocol involves small RNA isolation, 5'-capped RNA enrichment and library generation, followed by sequencing. Key advantages of csRNA-seq over other nascent RNA-seq methods include (i) decoupling of sample collection and processing, (ii) broad compatibility with diverse eukaryotic sample types and organisms, (iii) high-resolution data defining active regulatory elements and their properties and (iv) scalability. Importantly, purified RNA is non-infectious and can be isolated from inactivated samples, including clinical or pathogenic specimens, allowing safe transport and analysis under standard laboratory conditions. This protocol empowers researchers with minimal experience in nascent transcriptomics to study gene regulation, cis-regulatory elements and transcription dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.